ES2402540T3 - Derivados de2-oxo-3-bencil-benzoxazol-2-ona y compuestos relacionados como inhibidores de Met-quinasa para el tratamiento de tumores - Google Patents

Derivados de2-oxo-3-bencil-benzoxazol-2-ona y compuestos relacionados como inhibidores de Met-quinasa para el tratamiento de tumores Download PDF

Info

Publication number
ES2402540T3
ES2402540T3 ES08749391T ES08749391T ES2402540T3 ES 2402540 T3 ES2402540 T3 ES 2402540T3 ES 08749391 T ES08749391 T ES 08749391T ES 08749391 T ES08749391 T ES 08749391T ES 2402540 T3 ES2402540 T3 ES 2402540T3
Authority
ES
Spain
Prior art keywords
oxo
methyl
benzoxazol
phenyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08749391T
Other languages
English (en)
Spanish (es)
Inventor
Oliver Schadt
Dieter Dorsch
Frank Stieber
Andree Blaukat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2402540T3 publication Critical patent/ES2402540T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES08749391T 2007-06-06 2008-05-08 Derivados de2-oxo-3-bencil-benzoxazol-2-ona y compuestos relacionados como inhibidores de Met-quinasa para el tratamiento de tumores Active ES2402540T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007026341 2007-06-06
DE102007026341A DE102007026341A1 (de) 2007-06-06 2007-06-06 Benzoxazolonderivate
PCT/EP2008/003696 WO2008148449A1 (de) 2007-06-06 2008-05-08 2-oxo-3-benzyl-benzoxazol-2-one derivate und verwandte verbindungen als met-kinase inhibitoren zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
ES2402540T3 true ES2402540T3 (es) 2013-05-06

Family

ID=39739806

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08749391T Active ES2402540T3 (es) 2007-06-06 2008-05-08 Derivados de2-oxo-3-bencil-benzoxazol-2-ona y compuestos relacionados como inhibidores de Met-quinasa para el tratamiento de tumores

Country Status (18)

Country Link
US (2) US8071593B2 (enExample)
EP (1) EP2150551B1 (enExample)
JP (1) JP5662143B2 (enExample)
KR (1) KR20100031531A (enExample)
CN (1) CN101679401B (enExample)
AR (1) AR066892A1 (enExample)
AU (1) AU2008258366B2 (enExample)
BR (1) BRPI0812293A2 (enExample)
CA (1) CA2689554C (enExample)
DE (1) DE102007026341A1 (enExample)
EA (1) EA200901611A1 (enExample)
ES (1) ES2402540T3 (enExample)
IL (1) IL202505A (enExample)
MX (1) MX2009013077A (enExample)
PE (1) PE20090770A1 (enExample)
TW (1) TW200848030A (enExample)
WO (1) WO2008148449A1 (enExample)
ZA (1) ZA201000085B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
US8691838B2 (en) 2008-05-22 2014-04-08 Amgen Inc. Heterocycles as protein kinase inhibitors
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
DE102009003975A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
AU2012275499A1 (en) 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
CN103242345B (zh) * 2012-09-14 2015-03-11 日出实业集团有限公司 甲基吡啶磷中间体6-氯噁唑[4,5-b]吡啶-2(3H)酮的合成方法
AR095883A1 (es) 2013-04-18 2015-11-18 Astellas Pharma Inc Compuestos de acetamida heterocíclica
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
WO2020186202A1 (en) 2019-03-14 2020-09-17 Board Of Regents, The University Of Texas System Small molecule grb2 stabilizers for ras map kinase inhibition
CN115490578B (zh) * 2022-09-23 2023-12-22 江苏理工学院 一种碳同位素标记的三氯生的制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS421467B1 (enExample) * 1963-11-28 1967-01-24
DE3904797A1 (de) 1989-02-17 1990-08-30 Merck Patent Gmbh Nichtlinear optische materialien mit vicinalen donor- und akzeptorgruppen
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
US20040259863A1 (en) 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
AU2002353147A1 (en) * 2001-12-13 2003-06-30 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
JP2007516180A (ja) 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
DE102004036581A1 (de) 2004-07-28 2006-03-23 Robert Bosch Gmbh Verfahren zum Betreiben eines Hybridantriebs und Vorrichtung zur Durchführung des Verfahrens
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
CH697191A5 (de) 2004-07-29 2008-06-25 Biospectra Ag Mehrfach-Bioreaktorvorrichtung.
EP1621785A1 (en) 2004-07-30 2006-02-01 Mecos Traxler AG Method and apparatus for controlling a magnetic bearing device
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
DE102005055355A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CN101827595B (zh) 2007-10-16 2013-07-24 诺瓦提斯公司 作为神经肽y2受体调节剂的取代的哌嗪和哌啶类
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
CA2699631A1 (en) 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone compounds and p2x7 receptor inhibitors
EP2220048B1 (en) 2007-11-16 2017-01-25 Boehringer Ingelheim International GmbH Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
EP2225239B1 (en) 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
US8431580B2 (en) 2007-12-21 2013-04-30 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine H4 receptor antagonists
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009080364A1 (en) 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2010010150A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
JP5253143B2 (ja) 2008-12-26 2013-07-31 キヤノン株式会社 情報処理装置、情報処理装置の制御方法、及びプログラム
US20120028988A1 (en) 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
KR20100031531A (ko) 2010-03-22
IL202505A (en) 2014-11-30
US8431572B2 (en) 2013-04-30
ZA201000085B (en) 2010-09-29
AU2008258366A1 (en) 2008-12-11
CA2689554A1 (en) 2008-12-11
EP2150551B1 (de) 2013-01-16
EP2150551A1 (de) 2010-02-10
JP5662143B2 (ja) 2015-01-28
JP2010529051A (ja) 2010-08-26
US20100280030A1 (en) 2010-11-04
MX2009013077A (es) 2010-01-15
PE20090770A1 (es) 2009-06-24
BRPI0812293A2 (pt) 2014-11-25
AU2008258366B2 (en) 2013-02-21
CN101679401A (zh) 2010-03-24
US20110263596A1 (en) 2011-10-27
WO2008148449A1 (de) 2008-12-11
CN101679401B (zh) 2012-12-12
TW200848030A (en) 2008-12-16
AR066892A1 (es) 2009-09-16
IL202505A0 (en) 2010-06-30
CA2689554C (en) 2015-12-01
US8071593B2 (en) 2011-12-06
DE102007026341A1 (de) 2008-12-11
EA200901611A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
ES2373117T3 (es) Derivados de piridiazinona para el tratamiento de tumores.
US8431572B2 (en) 2-oxo-3-benzylbenzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumours
ES2572740T3 (es) Derivados de pirimidina como inhibidores de FAK
ES2362472T3 (es) Derivados de 2-bencilpiridazinona como inhibidores de la met-quinasa.
ES2444218T3 (es) Derivados de piridazinona
ES2388883T3 (es) Derivados de pirimidinil-piridazinona
ES2525120T3 (es) Derivados de 2-(heterociclilbencil)-piridazinona
ES2367152T3 (es) Derivados de ariléter piridazinona.
ES2394147T3 (es) Derivados de piridazinona
ES2400117T3 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]-triazolo[4,3-b]piridazina como inhibidores de metquinasa
ES2396301T3 (es) Derivados de piridazinona
MX2011001511A (es) Derivados de triazol biciclicos para el tratamiento de tumores.
ES2548517T3 (es) Derivados de 1-acildihidropirazol
ES2368001T3 (es) 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4]tiadiazinas sustituidas.
AU2009336847B2 (en) Benzothiazolone derivative
ES2400112T3 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]pirimidina
ES2426356T3 (es) Derivados de tiadiazinona
ES2405269T3 (es) Derivados de 3-(3-pirimidin-2-il-bencil)- [1,2,4]triazolo [4,3-b]piridazina
MX2010012804A (es) Derivados de dihidropirazol como moduladores de tirosina cinasa para el tratamiento de tumores.
ES2398023T3 (es) Derivados de piridazinonas